For a medicine or a medical device, a distributor is not just a sales channel — it is a regulatory decision. Who moves your product, who holds your registration, and whether they can reach hospitals and pharmacies under GDP and MDR rules decides whether you ever get paid. This is how to find and vet the right one.
In industrial sectors you pick a distributor for reach. In life sciences that logic fails: the wrong partner can be non-compliant, hold your registration hostage, or simply have no route into the hospitals and pharmacies that buy.
Two things make it different. First, the supply chain is regulated end to end — medicines move under Good Distribution Practice and serialisation; devices move under the MDR, which puts legal obligations on distributors themselves. Second, healthcare buyers are specific: a distributor with deep relationships in cardiology tells you nothing about access in ophthalmology. Fit, compliance and channel access matter far more than the size of a catalogue.
The best-covered distributor in Germany is worthless to you if they don't sell into your therapy area — compliantly.
What "distributor" means depends entirely on whether you sell a medicine or a device. Get the map right before you start looking.
Forget the generic industrial directories. Pharma and medtech partners are found through healthcare-specific networks, events and targeted research.
MEDICA / COMPAMED in Duesseldorf is the anchor event for medtech; therapy-specific congresses reach clinical buyers and their distributors directly.
BVMed and SPECTARIS for medtech; BAH, BPI and vfa for pharma; PHAGRO for wholesalers; bvitg for digital health — member directories and working groups.
Purchasing groups and clinic chains reveal which distributors already hold the relationships in your field. See hospital & tender access.
Key opinion leaders and specialist societies indicate which partners have credibility in a given indication — often the fastest validation.
Mapping competitor and reference-product supply chains shows the distributors already active in your exact segment.
Wholesale-dealer and GDP records help confirm a partner is licensed to handle your product class in the first place.
Coverage is the least important line. These are the criteria that decide whether a life-sciences distributor is right — and safe.
| Criterion | Why it decides the partnership |
|---|---|
| Therapy-area fit | Real relationships in your indication and care setting — not a broad catalogue. |
| Regulatory capability | Valid GDP / wholesale licence for medicines; ISO 13485 and MDR distributor duties for devices. |
| Channel access | A proven route into the hospitals, purchasing groups or pharmacies that buy your product. |
| Who holds the registration | Whether the partner expects to hold your MA / CE / registration — and how hard it is to take back. |
| Reimbursement & tender support | Ability to support DRG/NUB, AMNOG or tender processes — access, not just logistics. |
| Cold-chain & after-sales | Specialty handling for biologics; clinical and service support for devices. |
The general partner-selection logic — fit over coverage, long-term over transactional — is in our finding a distributor guide; this page adds the regulated layer on top of it.
This is the mistake that costs foreign life-sciences companies the most, and it is invisible until the relationship sours.
It is convenient to let one German partner be everything — distributor, importer, and the holder of your registration or Authorised Representative role. It is also how you hand a single company control of your legal permission to sell. If the commercial relationship breaks down, changing partners can mean re-registering, with the time and cost that implies.
Keep the roles separate on purpose: an independent EU Authorised Representative / PRRC (devices) or marketing-authorisation holder / QPPV (medicines) that you control, and distribution contracted alongside it. We set this out in local representation in Germany, and the classification that drives device obligations in MDR vs IVDR.
A structured, formal process. Distributors evaluate new partnerships on fit, evidence and long-term intent — not on a cold pitch.
Define how your product fits their portfolio and your therapy area — comparable products, evidence, pricing context and the target care setting. Partners respond when you complement, not compete with, their book.
Concise and specific: company, product, the clinical or commercial advantage, regulatory status (CE / MA), and the target indication and setting. Relevance to their existing clients beats reach.
Expect detailed discussion of clinical data, logistics, pricing, reimbursement pathway and after-sales or clinical support — formal and detail-oriented.
Partnerships build over time. Begin with a defined scope and expand into broader distribution as trust and performance are proven.
Partner search is our layer. We identify the right regulated distributors, check them, and structure the relationship so the market stays under your control.
The distributors and partners with real access in your therapy area and care setting — and the compliance to handle your product.
Regulatory capability (GDP / ISO 13485 / MDR), channel access, references and cultural fit — before you commit.
Contracting that separates distribution from who holds your registration, so a partner change never becomes a re-registration.
Through healthcare-specific channels, not open marketplaces: MEDICA and sector congresses, industry associations (BVMed, SPECTARIS, BAH, BPI, vfa, PHAGRO), hospital purchasing groups, KOL and clinical networks, and targeted supply-chain research. The goal is therapy-area fit and channel access, not the widest catalogue.
No. Full-line wholesalers (such as Phoenix, Noweda, Sanacorp or Alliance Healthcare) move product to pharmacies under Good Distribution Practice — that is regulated logistics. A commercial or licensing partner that markets and sells your medicine is a different role. Foreign companies often need both.
It can, but it usually should not. Letting one partner be distributor and Authorised Representative (or registration holder) hands them control of your legal permission to sell, and a partner change can force a re-registration. Keeping the Authorised Representative / PRRC or MA holder independent of distribution protects your market.
Confirm a valid quality system (ISO 13485), that they understand and meet MDR distributor obligations, whether they act as importer, and that they will not by default hold your CE registration. For medicines, confirm a valid wholesale-dealer / GDP licence for your product class.
Formally and specifically. Lead with fit to their portfolio and your therapy area, your regulatory status (CE / marketing authorisation), the clinical or commercial advantage and the target setting. Expect a detailed technical and commercial evaluation, and a relationship that starts scoped and expands over time.
Tell us about your product and target therapy area, and we'll identify, vet and approach the right regulated partners in Germany.